Enclomiphene on TRT: The Non-Fertility Use Case and What the Evidence Shows

Some clinicians consider adding enclomiphene to testosterone replacement therapy (TRT) to keep some of the testes' own signaling active, not only to protect fertility. The rationale comes from how the drug works. No trial has tested enclomiphene added to ongoing testosterone, so whether it does this for men on TRT is unknown.

What enclomiphene is, and why it gets lumped in with fertility

Enclomiphene is a selective estrogen receptor modulator, or SERM. It blocks estrogen receptors in the pituitary gland, which raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Those two signals tell the testes to make testosterone and sperm (BSSM 2026).

Clomiphene, the older SERM most people have heard of, is a mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis), with 30% to 50% of it the cis form. Zuclomiphene has a longer half-life, and in single-dose studies it stayed detectable for more than a month (Clomid label). In 15 men on long-term clomiphene, zuclomiphene levels ran about 20 times higher than enclomiphene levels (Helo et al., BJU Int 2017). In a retrospective review of 66 men who switched from clomiphene to enclomiphene, decreased libido, reduced energy, and mood changes were documented less often on enclomiphene (Saffati et al., Transl Androl Urol 2024).

Because enclomiphene raises LH and FSH, most of its research is about men with low testosterone who want to keep making sperm. In two phase III trials of overweight men with secondary hypogonadism (low testosterone from a pituitary or brain signal problem), enclomiphene raised testosterone, LH, and FSH and kept sperm counts in the normal range over 16 weeks. Testosterone gel raised testosterone too, but LH and FSH fell and sperm production dropped markedly (Kim et al., BJU Int 2016). That fertility focus is legitimate. It also left out a question some men on TRT ask for other reasons.

What TRT does to your own hormone signaling

Exogenous testosterone (testosterone given from outside the body) raises blood testosterone and treats the symptoms of hypogonadism. It also suppresses the body's own system. Through negative feedback, it lowers LH and FSH, which reduces sperm production and, as a result, testicular volume (Rolf and Nieschlag, Baillieres Clin Endocrinol Metab 1998). The DEPO-Testosterone label notes that spermatogenesis can be suppressed through feedback on FSH, and that oligospermia (low sperm count) can occur with prolonged use (DEPO-Testosterone label).

For many men, the visible result is smaller testicles. Some find that uncomfortable or distressing, and that is where enclomiphene comes up outside the fertility conversation.

The non-fertility use case: supporting the axis while on TRT

When a clinician considers adding enclomiphene to TRT, the aim is usually to keep some activity along the hypothalamic-pituitary-gonadal (HPG) axis, the signaling chain from the brain to the testes. The goal is not to replace the testosterone prescription.

The idea is that blocking estrogen's feedback at the pituitary might keep some LH and FSH coming even with testosterone in the system. That has not been shown. In the trials, enclomiphene was given instead of testosterone, and LH and FSH rose only in men who were not on testosterone (Kim et al., BJU Int 2016). A 2025 meta-analysis of randomized trials compared SERMs with placebo, testosterone gel, or hCG; none of those comparisons added a SERM to ongoing testosterone (Hohl et al., Arch Endocrinol Metab 2025). So any benefit for testicular volume or testicular function on TRT is a hypothesis.

The question tends to come up in three situations.

First, men starting TRT who are concerned about long-term suppression may ask their provider whether a SERM makes sense for them. Second, men changing their TRT protocol, such as switching delivery method or schedule, sometimes raise it during that window. Third, men coming off TRT sometimes find that their own production does not return quickly. The closest evidence here is small: in an open-label study of 12 men with secondary hypogonadism who stopped testosterone gel, enclomiphene raised testosterone and sperm counts, and testosterone fell back to pretreatment levels one month after enclomiphene stopped (Kaminetsky et al., J Sex Med 2013). Enclomiphene is not a guaranteed restart tool.

A fourth situation is symptom-based. Some men on TRT still report low energy, low libido, or mood symptoms with labs in range. A clinician may wonder whether suppressed gonadotropins play a part, but no study has tested whether adding enclomiphene helps those symptoms. This is a clinical judgment that needs current labs, not something to self-assess.

Who might reasonably bring it up with a clinician

Men already on provider-supervised TRT, with regular lab monitoring and specific concerns about HPG axis suppression, testicular changes, or a protocol change, are in a good position to raise this. It is a legitimate question for a men's health provider.

Some men need extra caution. The label for clomiphene, the mixture enclomiphene comes from, lists pulmonary embolism, thrombophlebitis, and stroke among postmarketing reports, which matters for anyone with a personal or family history of blood clots. It contraindicates clomiphene in liver disease or a history of liver dysfunction. It also says anyone with visual symptoms, such as blurring, spots, or flashes, should stop treatment and have a prompt eye exam (Clomid label).

Honest talk about side effects and trade-offs

Enclomiphene is not a neutral addition. In a phase II trial, estradiol rose along with testosterone and LH on enclomiphene, to levels similar to those on testosterone gel (Wiehle et al., Fertil Steril 2014). In the 66-man review, estradiol changed less on enclomiphene than on clomiphene (Saffati et al., Transl Androl Urol 2024). Gynecomastia (breast tissue growth) can develop on testosterone and occasionally persists (DEPO-Testosterone label). The AUA guideline ties estradiol testing to breast symptoms or gynecomastia (Expert Opinion), so new breast tenderness or swelling is a reason to contact your provider (AUA 2018).

Mood changes and lower libido were among the adverse effects documented in the retrospective review, less often on enclomiphene than on clomiphene (Saffati et al., Transl Androl Urol 2024). The clomiphene label lists migraine headache among postmarketing reports, and its visual symptoms become more common with higher total dose and longer use (Clomid label). No study gives side-effect rates for enclomiphene taken together with TRT.

The trade-off is individual. A man who finds testicular shrinkage uncomfortable or distressing may decide the possible benefit is worth the monitoring and side-effect risk. A man who isn't bothered by it may not. Either conclusion is reasonable, and it is the kind of decision a clinician should walk through with you.

Misconceptions that keep circulating online

First, enclomiphene does not replace TRT. It works through a different mechanism and does not supply testosterone. It depends on testes that can respond to LH and FSH, which is why the trials enrolled men with secondary hypogonadism, and the BSSM notes there may be limited success in some types of primary or functional hypogonadism (BSSM 2026). On TRT, it is at most an add-on.

Second, more is not better. Testosterone rose with dose across the 6.25 mg, 12.5 mg, and 25 mg doses studied (BSSM 2026), but side effects also matter, and the clomiphene label says visual symptoms increase with total dose and duration (Clomid label). The dose is your prescriber's decision, based on your labs and how you respond.

Third, enclomiphene on TRT is not a fertility plan. The AUA says exogenous testosterone should not be prescribed to men who are currently trying to conceive (Strong, Grade A). It says clinicians may use SERMs, hCG, or aromatase inhibitors in men with low testosterone who want to maintain fertility (Conditional, Grade C) (AUA 2018). If you want children now or soon, that conversation is about stopping or not starting testosterone, with semen analysis, not about adding a pill to TRT. AlphaMD's enclomiphene treatment page covers enclomiphene on its own.

Fourth, enclomiphene does not prevent all testicular changes. Since no trial has measured testicular volume in men taking it with TRT, expecting complete preservation is not supported.

Why self-experimenting with this combination is a bad idea

Combining enclomiphene with TRT without medical supervision creates a hormonal picture that needs labs to interpret. On testosterone alone, hemoglobin and hematocrit (the share of your blood made of red cells) should be checked periodically (DEPO-Testosterone label), and testosterone every 6 to 12 months (AUA statement 30, Expert Opinion) (AUA 2018). Without those labs, plus whatever else your prescriber orders, there is no way to know whether the combination is doing what was intended or causing problems that have no symptoms yet.

Mood changes from a SERM can also come on gradually enough that a man does not connect them to the medication without an outside view.

Enclomiphene is easy to find through online channels. That availability does not make an unsupervised combination safer.

Questions worth bringing to a clinical conversation

If you are on TRT and wondering whether enclomiphene belongs in your plan, useful questions for your provider include: What does my current lab picture suggest about my HPG axis? Is testicular shrinkage something we should track, and does it matter clinically in my case? If I ever want to stop TRT, what would that look like, and would other medications play a role? Could any of my symptoms reflect suppressed gonadotropins rather than my testosterone level?

A good clinical discussion covers your history, labs, goals, risk profile, and the monitoring a SERM would need. It will not promise outcomes.

Bottom line

Adding enclomiphene to TRT for reasons other than fertility is a reasonable question to raise, but it rests on mechanism, not trial results. The trials gave enclomiphene instead of testosterone, and the BSSM describes the evidence as small, short-term studies with limited safety and fertility data (BSSM 2026). If you're interested, decide it with a provider who will monitor your labs.